Trial Profile
A Phase 2 Trial of Carfilzomib Consolidation After Autologous Stem Cell Transplantation for Multiple Myeloma(CARAMEL 2)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2016
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms CARAMEL 2
- 15 Dec 2016 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
- 15 Dec 2016 Planned End Date changed from 1 May 2016 to 1 Oct 2014.
- 15 Dec 2016 Planned primary completion date changed from 1 May 2016 to 1 Sep 2014.